Skip to main
XBIO
XBIO logo

Xenetic Biosciences (XBIO) Stock Forecast & Price Target

Xenetic Biosciences (XBIO) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xenetic Biosciences Inc. has reinforced its positive outlook through the extension of its research and development partnership with The Scripps Research Institute, underscoring its commitment to advancing innovative immuno-oncology technologies. Recent preclinical studies indicate that the company's DNase technology significantly reduces tumor burden and enhances survival rates in murine models, suggesting strong therapeutic potential as an adjunctive treatment for difficult-to-treat cancers. Furthermore, strategic collaborations, such as the agreement with PeriNess, are anticipated to accelerate the clinical development of the DNase I based oncology program, strengthening Xenetic’s pipeline as it gears up for clinical trials in 2025.

Bears say

Xenetic Biosciences faces significant risks that could adversely affect its valuation, primarily including the potential for failed or inconclusive clinical trials that could halt the advancement of its innovative therapies. The company's reliance on external funding to support its development programs raises concerns about its ability to secure sufficient capital, which is critical for long-term sustainability and growth. Additionally, commercialization risks associated with bringing its therapies to market could further complicate financial stability and undermine investor confidence.

Xenetic Biosciences (XBIO) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xenetic Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xenetic Biosciences (XBIO) Forecast

Analysts have given Xenetic Biosciences (XBIO) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Xenetic Biosciences (XBIO) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xenetic Biosciences (XBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.